Drugmakers are pouring billions into U.S. production, but building enough plants won’t matter without enough skilled workers ...
The line between educating healthcare professionals and wooing them can still be fuzzy, which is impacting what doctors ...
Despite an uptick in dealmaking and IPOs, a selective funding market and scientific setbacks are still pushing some biotechs ...
Ai3Bio recently emerged from stealth with preclinical programs aimed at what it believes could be a root cause of autoimmune ...
A new report argues that more flexible eligibility criteria could widen pharma’s clinical trial pool without sacrificing ...
Turn Therapeutics CEO Bradley Burnam didn’t set out to recruit two U.S. regulatory big wigs for his biotech. But common scientific interests, professional connections and an interview on the CEO’s ...
Right now is “singularly, the most exciting moment” in Daiichi Sankyo’s 100-year history, said Ken Keller, CEO and president of the company’s U.S. business and head of its global oncology unit. Riding ...
The FDA green-lit four drugs last year without any U.S. trial participants, according to CDER’s drug trials snapshot report, which summarizes the various demographics of clinical trials for approved ...
Last year, Bristol Myers Squibb put a spotlight on the kind of cash that comes with pharma’s conviction in a new oncology strategy. The drugmaker agreed to pay BioNTech $1.5 billion upfront and ...
As patent protection for the cancer juggernaut Keytruda approaches a critical juncture, Merck & Co. won’t give up market share without a fight. The company revealed this week that a subcutaneous ...
Job cuts continue to climb and pervade the biopharma sector this year, defying hopes that 2024 marked a peak. After shedding more than 14,000 jobs in all of 2024, the industry surpassed 13,000 layoffs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results